MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Kodu・Aktsiate loetelu・Agios Pharmaceuticals Inc

Agios Pharmaceuticals Inc

Suletud

SektorTervishoid

27.18 -0.48

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

26.63

Max

27.58

Põhinäitajad
By Trading Economics
Sissetulek	8.6M -103M
Müük	425K 13M
P/E Sektori keskmine	3.836 88.032
Kasumimarginaal	-803.051
Töötajad	486
EBITDA	8.7M -102M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+38.53% upside

Turustatistika
By TradingEconomics
Turukapital	-934M 1.6B
Eelmine avamishind	27.66
Eelmine sulgemishind	27.18

Uudiste sentiment

By Acuity

15%

85%

18 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

28.04 / 30.06 Toetus ja vastupanu

Agios Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. nov 2025, 15:05 UTC

Tulu

Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Nvidia, Lowe's, Target, Semrush, MP Materials, Plug Power, Dycom, and More -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Agios Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

38.53% tõus

12 kuu keskmine prognoos

Keskmine 37.86 USD 38.53%

Kõrge 62 USD

Madal 25 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Agios Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Agios Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

28.04 / 30.06Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

The bullish and bearish events are balanced.

Sentiment

By Acuity

18 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.